Cervical cancer, version 2.2015: Featured updates to the NCCN guidelines featured updates to the NCCN guidelines

Wui Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, Kathleen R. Cho, Christina Chu, David Cohn, Marta Ann Crispens, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Ernest Han, Warner K. Huh, John R. Lurain, David Mutch, Amanda Nickles Fader, Steven W. RemmengaR. Kevin Reynolds, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Catheryn M. Yashar, Nicole R. McMillian, Jillian L. Scavone

Research output: Contribution to journalReview articlepeer-review

256 Scopus citations

Abstract

The NCCN Guidelines for Cervical Cancer provide interdisciplinary recommendations for treating cervical cancer. These NCCN Guidelines Insights summarize the NCCN Cervical Cancer Panel's discussion and major guideline updates from 2014 and 2015. The recommended systemic therapy options for recurrent and metastatic cervical cancer were amended upon panel review of new survival data and the FDA's approval of bevacizumab for treating late-stage cervical cancer. This article outlines relevant data and provides insight into panel decisions regarding various combination regimens. Additionally, a new section was added to provide additional guidance on key principles of evaluation and surgical staging in cervical cancer. This article highlights 2 areas of active investigation and debate from this new section: sentinel lymph node mapping and fertility-sparing treatment approaches.

Original languageEnglish
Pages (from-to)395-404
Number of pages10
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Dive into the research topics of 'Cervical cancer, version 2.2015: Featured updates to the NCCN guidelines featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this